Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity.
Level V
Where this comes from
- Record sourced from PubMed, PMID 27586383.
- Also identified by DOI 10.1038/nrrheum.2016.145 and PMC identifier 8502420.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adalimumab, an anti-TNF monoclonal antibody used to treat rheumatoid arthritis and other autoimmune disorders, paradoxically enhances the capacity of TNF to expand TNF receptor type II-expressing regulatory T cells. This provocative finding opens a new avenue for exploring the mechanisms that underlie efficacy, non-responsiveness and adverse effects associated with therapeutic targeting of TNF signalling.
Medical subject headings
- Autoimmunity
- Tumor Necrosis Factor-alpha